These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28826592)

  • 1. Genetic basis for response to cancer immunotherapy.
    Gruber K
    Lancet Oncol; 2017 Sep; 18(9):e521. PubMed ID: 28826592
    [No Abstract]   [Full Text] [Related]  

  • 2. Pooled in vivo screens for cancer immunotherapy target discovery.
    Lane-Reticker SK; Manguso RT; Haining WN
    Immunotherapy; 2018 Mar; 10(3):167-170. PubMed ID: 29370725
    [No Abstract]   [Full Text] [Related]  

  • 3. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
    Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CRISPR System and Cancer Immunotherapy Biomarkers.
    Balan V; Wang J
    Methods Mol Biol; 2020; 2055():301-322. PubMed ID: 31502158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-viral vector-based genome editing for cancer immunotherapy.
    Fang T; Chen G
    Biomater Sci; 2024 Jun; 12(12):3068-3085. PubMed ID: 38716572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
    Golkaram M; Zhao C; Kruglyak K; Zhang S; Bilke S
    PLoS Comput Biol; 2020 Nov; 16(11):e1008332. PubMed ID: 33166276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
    Chen M; Xu J; Zhou Y; Zhang S; Zhu D
    Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigens in cancer immunotherapy.
    Schumacher TN; Schreiber RD
    Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CANCER IMMUNOLOGY. The "cancer immunogram".
    Blank CU; Haanen JB; Ribas A; Schumacher TN
    Science; 2016 May; 352(6286):658-60. PubMed ID: 27151852
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene-expression profiling to predict responsiveness to immunotherapy.
    Jamieson NB; Maker AV
    Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
    Zhang X; Cheng C; Sun W; Wang H
    Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-scale public data reuse to model immunotherapy response and resistance.
    Fu J; Li K; Zhang W; Wan C; Zhang J; Jiang P; Liu XS
    Genome Med; 2020 Feb; 12(1):21. PubMed ID: 32102694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A methodological framework to enhance the clinical success of cancer immunotherapy.
    Hoos A; Britten CM; Huber C; O'Donnell-Tormey J
    Nat Biotechnol; 2011 Oct; 29(10):867-70. PubMed ID: 21997622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.